STOCK TITAN

PMV Pharmaceuticals (PMVP) SEC Filings

PMVP NASDAQ

PMV Pharmaceuticals filings document a clinical-stage precision oncology company focused on small molecule therapies targeting p53. The company’s Form 8-K reports disclose operating results, financial condition updates, Regulation FD materials, and rezatapopt clinical disclosures from the PYNNACLE study in tumors with a TP53 Y220C mutation.

Proxy materials describe annual meeting matters, board composition, stockholder voting procedures, and governance practices. The filing record also identifies PMV’s Nasdaq-listed common stock and includes risk and forward-looking-statement disclosures tied to drug development, regulatory pathways, capital resources, and clinical-stage biotechnology operations.

Rhea-AI Summary

PMV Pharmaceuticals, Inc. (PMVP) is the issuer in an amended beneficial-ownership report filed by Tang Capital Management, LLC; Kevin Tang, manager of Tang Capital Management and Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc.; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; and Tang Capital Partners IV, Inc. Tang Capital Management and Kevin Tang each report shared beneficial ownership of 7,572,727 shares, or 9.99%, comprising 7,285,085 common shares and 287,642 shares currently issuable upon warrant exercise. These are reports of the same shared position, not separate share blocks.

The disclosures also state that Tang Capital Management and Kevin Tang each beneficially own 11,000,000 pre-funded warrants and 14,040,000 warrants to purchase common stock, each exercisable for one share. Tang Capital Partners, LP may not exercise warrants if doing so would take its combined ownership with affiliates and any group above 9.99%; it may raise the limit to no more than 19.99% by written notice, effective 61 days after notice, subject to the stated Nasdaq qualification.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
ownership
-
Rhea-AI Summary

PMV Pharmaceuticals, Inc. reported a third-quarter net loss of $34.372 million, versus $21.059 million a year earlier. The loss included a $12.781 million expense from remeasuring common stock warrants and $2.344 million of offering costs allocated to the warrant liability.

For the first nine months, operating cash use was $52.440 million, compared with $56.388 million in 2025. Cash, cash equivalents and marketable securities were $108.5 million at September 30, 2026. Management believes these resources will fund planned operations for at least one year from the report date, excluding proceeds from warrant exercises, and concluded there was no longer substantial doubt about PMV’s ability to continue as a going concern.

The September 2, 2026, public offering generated $46.9 million in net proceeds and included 22,055,000 common shares, pre-funded warrants for 19,900,000 shares and common stock warrants for 41,955,000 shares. Enrollment of platinum-resistant/refractory ovarian cancer patients for the Phase 2 primary analysis is complete; PMV plans to submit an initial NDA via accelerated approval in the first quarter of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.40%
Tags
quarterly report
-
Rhea-AI Summary

PMV Pharmaceuticals reported a third-quarter 2026 net loss of $34.4 million, compared with $21.1 million a year earlier. The increase was primarily due to a $12.8 million non-cash loss from the change in fair value of warrant liability and $2.3 million of offering costs allocated to warrant liability, both related to the closed $50 million August 2026 public offering. Cash, cash equivalents and marketable securities totaled $108.5 million as of September 30, 2026, with expected cash runway into the first quarter of 2028. Nine-month net cash used in operations was $52.4 million, compared with $56.4 million.

Interim rezatapopt data from the PYNNACLE Phase 2 ovarian cancer cohort, with a May 14, 2026 cutoff, showed a 46% overall response rate (35 of 76 patients) and a median duration of response of 10.0 months for confirmed responses. Enrollment for the ovarian cohort's primary analysis is complete; PMV plans to present updates on all pivotal trial cohorts, including those data, at ENA 2026. It plans to submit a rezatapopt NDA for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.40%
Tags
current report
Rhea-AI Summary

PMV Pharmaceuticals, Inc. director Matthew Joseph Eckler received a direct grant of stock options covering 84,000 shares of common stock on October 1, 2026, at an exercise price of $1.75 per share. The options vest in 36 equal monthly installments beginning November 1, 2026, and expire October 1, 2036.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.55%
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.55%
Tags
insider
-
Rhea-AI Summary

PMV Pharmaceuticals, Inc. appointed Dr. Matthew Eckler to its board on October 1, 2026, with a term ending at the 2029 Annual Meeting of Stockholders. As a non-employee director, he is entitled to $40,000 in annual cash compensation, plus additional cash compensation for committee service. He received an initial stock option award for 84,000 shares, made on the first trading date on or after his appointment; PMV expects to grant an annual option to purchase 42,000 shares effective on each annual meeting date.

Enrollment is complete in the Phase 2 monotherapy portion of the PYNNACLE trial. PMV plans to submit a New Drug Application for accelerated approval of rezatapopt in the first quarter of 2027 for platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation. The FDA granted Fast Track designation for locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for TP53 Y220C-positive ovarian, fallopian tube and primary peritoneal cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
current report
Rhea-AI Summary

PMV Pharmaceuticals, Inc. (PMVP) is reported to have a significant shareholder group led by Samsara BioCapital entities and Srinivas Akkaraju. The reporting persons disclose beneficial ownership of 7,577,467 shares of common stock, representing 9.99% of PMV’s outstanding common stock.

The holdings include, for each of Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P., 3,620,000 common shares, Pre-Funded Warrants exercisable for up to 3,400,000 shares, and Common Warrants exercisable for up to 7,020,000 shares. All percentages are calculated using 53,458,058 shares outstanding as of August 14, 2026 plus 22,055,000 shares issued in PMV’s September 2, 2026 equity offering and Warrants exercisable within 60 days.

Each Warrant contains a Beneficial Ownership Blocker that prevents exercises which would cause the holder and its affiliates to own more than 9.99% of PMV’s common stock, limiting further Warrant exercise above 7,577,467 shares currently attributed to the reporting group.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.15%
Tags
ownership
-
Rhea-AI Summary

PMV Pharmaceuticals, Inc. (PMVP) priced an underwritten public offering of (i) 22,055,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 19,900,000 shares, and (ii) accompanying warrants to purchase 41,955,000 shares of common stock. Each share plus accompanying warrant is priced at $1.21, and each pre-funded warrant plus accompanying warrant at $1.20999, reflecting a $0.00001 pre-funded warrant exercise price. The company expects gross proceeds of about $50.8 million and net proceeds of about $47.0 million, and plans to use them, together with existing cash, primarily to fund late-stage clinical development, regulatory submission and commercialization preparation for rezatapopt. Based on its current plan, PMV believes this financing, together with existing cash, will fund operations into the first quarter of 2028. The accompanying warrants are immediately exercisable at $1.21 per share for five years and include a reset mechanism and potential Mandatory Exercise tied to FDA acceptance of the company’s NDA for rezatapopt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
current report
-
Rhea-AI Summary

PMV Pharmaceuticals, Inc. (PMVP) is conducting a primary offering of 22,055,000 shares of common stock and pre-funded warrants for 19,900,000 shares, each sold with a common stock warrant, for total gross proceeds of $50.8 million at approximately $1.21 per unit. The offering also registers 41,955,000 common stock warrants, immediately exercisable for five years at an initial exercise price of $1.21 per share, with price and share-count adjustments tied to FDA acceptance of an NDA for rezatapopt.

PMV estimates net proceeds of about $47.0 million after fees and expenses, on top of $79.4 million in cash and equivalents as of June 30, 2026, and expects this liquidity to fund operations into the first quarter of 2028. Proceeds are earmarked primarily for late-stage development, regulatory submission and commercialization preparation for lead candidate rezatapopt in TP53 Y220C–mutant ovarian cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
prospectus
Rhea-AI Summary

PMV Pharmaceuticals, Inc. (PMVP) is updating its previously filed at-the-market equity program. The company had registered the offer and sale of its common stock under an Open Market Sale Agreement with Jefferies LLC, permitting issuances of shares with an aggregate offering price of up to $113,792,846.40 from time to time. This supplement terminates the company’s continuous offering under that ATM prospectus supplement, and PMV Pharmaceuticals states that no shares of common stock were sold under the program. The termination does not otherwise change the underlying sales agreement or the parties’ rights and obligations under it.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.61%
Tags
prospectus

FAQ

How many PMV Pharmaceuticals (PMVP) SEC filings are available on StockTitan?

StockTitan tracks 51 SEC filings for PMV Pharmaceuticals (PMVP), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for PMV Pharmaceuticals (PMVP)?

The most recent SEC filing for PMV Pharmaceuticals (PMVP) was filed on November 16, 2026.